Abel Tilahun

Learn More
In recent years, a lot of attention is placed on the selection and evaluation of biomarkers in microarray experiments. Two sets of biomarkers are of importance, namely therapeutic and prognostic. The therapeutic biomarkers would give us information on the response of the genes to treatment in relation to the response of the clinical outcome to the same(More)
The number of potential surrogate markers for clinical-trial endpoints is increasing rapidly, not in the least owing to the availability of biomarkers. At the same time, considerable development has taken place regarding statistical evaluation paradigms for such markers. As a consequence, such endpoints are given more extensive consideration for practice(More)
  • 1